Singapore markets closed

Agios Pharmaceuticals, Inc. (AGIO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
32.00-0.27 (-0.84%)
As of 10:05AM EST. Market open.

Agios Pharmaceuticals, Inc.

88 Sidney Street
Cambridge, MA 02139
United States
617 649 8600
https://www.agios.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees383

Key executives

NameTitlePayExercisedYear born
Mr. Brian M. Goff M.B.A.CEO & Director1.23MN/A1969
Ms. Cecilia JonesChief Financial Officer403.36kN/A1975
Mr. James William BurnsCorporate Secretary & Chief Legal Officer660.33kN/A1978
Dr. Sarah Gheuens M.D., Ph.D.Chief Medical Officer and Head of Research & Development769.2kN/A1981
Dr. Lewis Clayton Cantley Ph.D.Co-Founder & Member of Scientific Advisory Board50kN/A1949
Dr. Tak Wah Mak D.Sc., FRSC, Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1946
Dr. Craig B. Thompson M.D.Co-Founder & Chairman of Scientific Advisory BoardN/AN/A1953
Dr. Shin-San Su Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/A1956
Mr. T. J. Washburn Jr.Principal Accounting OfficerN/AN/A1981
Dr. Clive Patience Ph.D.Chief Technical Operations OfficerN/AN/A1964
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Agios Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 March 2024 is 5. The pillar scores are Audit: 5; Board: 3; Shareholder rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.